Evaluation of the efficacy of colestipol for phosphate reduction in chronic kidney disease - a feasibility study

Phase 2

Completed

• Conditions: Hyperphosphataemia; Chronic Kidney disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12614000983606
• Lead Sponsor: Dr Christoper Hood

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-09-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with end-stage kidney disease stable on thrice weekly haemodialysis for at least 3 months. Stable dose of phosphate binder for at least one month prior to screening, stable dose of vitamin D supplement and serum phosphate >=1.6mmol/L and <=3.5mmol/L after first washout phase.

Exclusion Criteria

Patients are excluded if they have a history of clinically significant gastrointestinal motility disorder, dysphagia or swallowing disorder, if they require warfarin or digoxin treatment, if they have a history of alcohol or substance abuse, if they need to change their dialysis prescription during the study period, if they need oral calcium, magnesium, aluminium, or iron-containing preparations during the trial other than nocturnal calcium for treating hypocalcaemia developing during the trial period.

Study & Design

• Study Type: Interventional
• Study Design: Not specified